April 29, 2026 -- Tacalyx, a leader in the discovery and development of cancer therapies directed at Tumour Associated Carbohydrate Antigens (TACAs), announces the selection of its first clinical candidate, TCX-201, which is being advanced toward clinical development with the goal of filing a clinical trial application (CTA) in 2027. In support of this progress, the company has secured €11 million in a first closing of its seed extension round from its existing international investor syndicate,

Funds will support one of the largest interventional clinical trials of a full-spectrum microbiome product, and the largest ever to be conducted in IBS Dosing of first patient of the Phase 2b ‘RISE’ trial anticipated in Q2 2026, and topline efficacy data anticipated in H2 2027 29 April 2026. EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in-class microbiome therapies for gut health, today announces the completion of a £19m ($25m) financing to advance its lead

Onco3R Therapeutics unveiled a new name and a fresh financing on Tuesday. Now operating as Coultreon Biopharma, the biotech bagged a $125-million A round backed by big pharma to begin Phase II studies of its lead candidate, COL-5671 (formerly O3R-5671). The company is developing therapeutics that modulate salt-inducible kinases (SIKs), a protein family linked to inflammatory pathway regulation, to treat autoimmune diseases. COL-5671 is an oral, once-daily inhibitor of SIK3, a target that Coultr

April 28, 2026 -- AcuraStem, a biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company $7.5 million in grant funding to support the advancement of its lead clinical candidate, AS-241, toward first–in–human testing. AS-241 is an antisense oligonucleotide (ASO) designed to address a core molecular co

Financing led by institutional life sciences investor, with participation from new and existing investors Capital expected to support expansion of CDMO platform and advancement of customer programs April 24, 2026 -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics and the owner of Scinai Biopharma Services Ltd., a contract development and manufacturing organization (

April 22, 2026 -- Courier Health, the leading technology company for managing patient experiences, today announced it has raised a $50 million Series B funding round led by Oak HC/FT, with participation from existing investors including Norwest and Work-Bench. This latest investment will fuel continued product innovation and solidify Courier Health's position as the leading solution to orchestrate and personalize patient journeys across the life sciences industry. Despite immense clinical innov

April 21, 2026 -- Ionetix Corporation ("Ionetix"), a leading particle accelerator company focused on the medical, materials testing and nuclear energy space announced today it raised more than $30 million in a private placement offering at $3.00 per share. In addition, the company completed a go-public reverse merger transaction with JDEV Acquisition Corp., which has been renamed Ionetix Corp. Ionetix's patent-protected superconducting cyclotron technology supports unique particle accelerator s

April 17, 2026 -- MastCURe, a high-profile research consortium, has been awarded €1.3M in funding from the Eureka Eurostars program. The collaboration comprising Allegria Therapeutics, Cube Biotech, and the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Immunology and Allergology IA aims to transform the treatment of chronic urticaria, a debilitating mast cell-driven skin disease affecting millions worldwide. MastCURe's innovative approach directly and selectively targets

Kailera Therapeutics has pulled off one of the largest biotech IPOs on record, raising $625 million as investor appetite for next-generation obesity drugs shows no signs of abating. The company priced 39.1 million shares at $16 each, which was the top end of its range. Certain existing shareholders had signaled confidence ahead of the debut, indicating plans to purchase about $225 million in the offering, or about 45% of the deal. The offering surpasses Moderna's debut in 2018 when the mRNA va

Storm Therapeutics has closed a $56 million series C financing as the British biotech kicks off a phase 2 sarcoma trial of its RNA-modifying enzyme inhibitor. Proceeds from the financing will support the mid-stage study of a METTL3 inhibitor dubbed STC-15, which is designed to reprogram malignant progenitor cells by modulating mRNA methylation, according to an April 16 release. The trial, for which the first patient has now been dosed, will assess STC-15 as a monotherapy in various sarcoma indi